ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2186

Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies

Christian Lood and Grant C. Hughes, Medicine/Rheumatology, University of Washington, Seattle, WA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ANCA, Auto-immunity, autoantibodies, drug toxicity and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases

Session Type: Abstract Submissions (ACR)

Background/Purpose: Illicit cocaine use is associated with the development of serum anti-neutrophil cytoplasmic autoantibodies (ANCA) and a variety of clinical manifestations. However, the mechanisms linking cocaine use and autoimmunity remain obscure. A causal link between cocaine use and ANCA is suggested by known immunostimulatory properties of cocaine, and its frequent contamination with levamisole, an immunomodulatory chemical. Here, we describe the immunologic and clinical characteristics of a series of cocaine users found to have extremely high-titer serum ANCA. The purpose of this report is to generate testable hypotheses regarding possible links between cocaine use and autoimmunity.

Methods: Chart review of 12 consecutive patients referred for rheumatologic evaluation at 2 tertiary referral centers from 2008 and 2013 for active cocaine use and high-titer serum ANCA. Clinical and immunologic parameters with complete or near-complete data sets were chosen.

Results: Results are summarized in the table below. The majority of subjects were female users of crack cocaine. Half presented with hematologic abnormalities, but only a minority (2) presented with purpura, a frequently reported manifestation. Interestingly, 2 patients presented with diffuse alveolar hemorrhage (DAH) not readily explained by vasculitis or cryoglobulinemia. 3 patients presented glomerular disease. One presented with supraglottic inflammation, and another with ischemic bowel. Arthralgia/arthritis was common.

All patients had high-titer P-ANCA reactivity with variable MPO and PR reactivity, suggesting reactivity against unmeasured neutrophil antigens (Ags). High-titer ANA was not observed in any patient, although some displayed reactivity against select ANA-associated Ags. Most patients showed serum IgM (but not IgG) cardiolipin and/or b2-glycoprotein reactivity, along with frequent lupus inhibitor positivity, again consistent with previous reports. Hypocomplementemia was frequent among those patients with active HCV infection. Finally, there were no clear correlations between route/nature of cocaine exposure and either clinical or immunologic features.

Conclusion: We observed a wide variety of clinical manifestations in cocaine users with high-titer serum ANCA reactivity. Immunologically, patients were more homogeneous, showing near-exclusive P-ANCA reactivity, frequent IgM (but not IgG) cardiolipin/b2-glycoprotein reactivity and a complete absence of significant titer ANA – suggesting loss of immune tolerance to a limited set of self-Ags. That MPO reactivity was variably present further suggests P-ANCA reactivity was directed against other perinuclear neutrophil cytoplasmic Ags. The nature of these Ags in cocaine-users, as well as the effects of cocaine and levamisole on neutrophils, are the subjects of ongoing investigation.

Age at presentation

42

49

52

49

28

46

54

35

53

39

43

46

Sex

F

F

F

F

F

F

F

F

M

F

F

F

Clinical manifestations

Skin

P

–

–

–

–

P

–

–

–

U

U

U

Hematologic

Pan

Pan

Pan

N

N

–

–

–

–

–

–

N

Kidney

–

–

–

GN+

Amyloid

–

GN-

–

–

–

–

–

Lung

–

DAH

–

DAH

–

–

–

–

–

–

–

–

Other

–

–

–

–

Arth

GI isch.

–

Glottitis

Arth

Arth

Arth

Arth

Immunologic parameters

ANCA IF (titer)

1:4,096

1:4,096

>1:65,536

>1:65,536

1:4,096

1:4,096

1:16,384

1:16,384

1:4,096

1:8,192

1:16,384

1:1,024

ANCA IF (pattern)

P,C

P

P

P

P

P

P,C,N

P

P

P

P

P

anti-PR3

+

+

+

–

–

+

+

–

–

–

–

–

anti-MPO

–

–

+

+

–

+

+

–

+

+

+

+

ANA IF (titer)

–

–

–

–

1:80

1:80

–

–

–

–

–

–

ANA-assoc. autoAbs

NT

–

–

SSA, RibP

Ch

dsDNA, Ch

SSA, Ch

dsDNA, Ch

dsDNA, Ch

–

–

NT

Anti-cardiolipin

IgM

IgM

–

IgM

IgM

NT

IgM

IgM

NT

IgM

IgM

NT

Anti-b2 glycoprotein

NT

IgM

IgM

IgM

–

NT

–

IgM

NT

IgM

–

NT

Lupus inhibitor

–

+++

+/-

–

+++

NT

NT

+/-

NT

+

–

++

Rheumatoid factor

–

–

–

–

–

NT

–

–

–

–

–

–

Hypocomplementemia

–

–

+

+

+

+

+

+

–

–

–

–

Cryoglobulinemia

–

+/-

+

–

–

–

+

–

NT

+

–

–

Active viral infection

–

–

HCV

HCV

HCV

HCV

HCV

–

HCV

–

–

–

Nature of cocaine exposure

C

C

P

P

IV

IV, C

IV, C

C

C

P

C

C

Abbreviations. NT, not tested, -, negative/normal, Skin (P, purpura; U, ulcers), Hematologic (Pan, pancytopenia; N, neutropenia), Kidney (GN+, glomerulonephritis – immune complex; GN-, glomerulonephritis – pauci-immmune), Lung (DAH, diffuse alveolar hemorrhage), Other (Arth, arthralgia/arthritis), ANCA IF pattern (P, perinuclear; C, cytoplasmic; N, nuclear), ANA-associated Abs (RibP, ribosomal P; Ch, chromatin), Nature of cocaine exposure (C, crack/smoked/inhaled; P, powder/inhaled; IV, intravenous)


Disclosure:

C. Lood,
None;

G. C. Hughes,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/clinical-and-immunologic-correlates-in-cocaine-users-with-serum-anti-neutrophil-cytoplasmic-antibodies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology